The PI3K/PTEN/Akt signaling pathway has emerged in recent years as a main player in human cancers, increasing proliferation and decreasing apoptosis of transformed cells, and thus becoming a potential target for therapeutic intervention. Our previous data have demonstrated that Akt-mediated signaling is of a key relevance in the mouse skin carcinogenesis system, one of the best-known models of experimental carcinogenesis. Here, we investigated the involvement of several pathways as mediators of Aktinduced increased proliferation and tumorigenesis in keratinocytes. Tumors produced by subcutaneous injection of Akt-transformed keratinocytes showed increased Foxo3a phosphorylation, but no major alterations in p21 Cip1/WAF1 , p27
Kip1 or mdm2 expression and/or localization. In contrast, we found increased expression and nuclear localization of DNp63, b-catenin and Lef1. Concomitantly, we also found increased expression of cmyc and CycD1, targets of the b-catenin/Tcf pathway. Such increase is associated with increased phosphorylation and stabilization of c-myc protein as well as increased translation of c-myc and CycD1 due to mTOR activation. Using immunohistochemistry approaches in samples of oral dysplasias and human head and neck squamous cell carcinomas, we confirmed that increased Akt activation significantly correlates with increased DNp63 and CycD expression, c-myc phosphorylation and nuclear accumulation of b-catenin. Collectively, these results demonstrate that Akt is able to transform keratinocytes by specific mechanisms involving transcriptional and post-transcriptional processes.
Introduction
Aberrant activation of the PI3K/PTEN/Akt pathway has been widely implicated in many human cancers. Multiple oncogenic insults can increase Akt activity, affecting a number of putative substrates, which includes a plethora of different signaling intermediates whose activity primarily modulates cell death and proliferation (reviewed in Lawlor and Alessi, 2001; Vivanco and Sawyers, 2002; Luo et al., 2003) . As a consequence, possible therapies targeting the Akt pathway alone, or in conjunction with other chemotherapeutics, might be suitable cancer treatments (Luo et al., 2003) . However, this possibility should be preceded by a complete characterization of Akt responses in model systems. Mouse cancer models have been invaluable in understanding the process of tumorigenesis: they allow defined tests of tumor genetics, close analysis of tumor pathology and validation of therapeutic targets. The mouse skin carcinogenesis system is one of the bestcharacterized models and has provided an important instrumental framework for understanding many of the concepts currently applied to human cancers. This system displays many parallelisms with certain human tumors, such as head and neck squamous cell carcinomas (HNSCC) (reviewed in Slaga et al., 1996; Yuspa et al., 1996) . Others and we have provided evidence on the particular relevance of the PI3K-Akt pathway in mouse skin carcinogenesis Segrelles et al., 2002; Suzuki et al., 2003) . However, it is important to consider that many genetic events and general changes in the expression profile occurred during the malignant progression of mouse skin tumors, thus making it difficult to ascertain what possible targets are fundamental and what are secondary outcome of the process. As a consequence, possible models that show increased tumorigenic properties upon a limited and controlled number of experimental alterations are also relevant. We have used the PB keratinocyte cell line for these purposes. These cells were obtained from a chemically induced mouse skin papilloma, but they do not show increased EGFR expression nor mutations in Ha-ras gene (Yuspa et al., 1986; Casanova et al., 2002) . Moreover, when PB keratinocytes are used in xenograft experiments, they are poorly tumorigenic: few tumors are generated, and those obtained display very long latency, reduced growth rate and highly differentiated phenotypes (Yuspa et al., 1986; Casanova et al., 2002; Segrelles et al., 2002) . On the other hand, increased expression of Akt, and thus increased activity, promoted a dramatic enhancement in tumorigenic behavior, with reduced latency, increased growth rate and less differentiated phenotypes (Supplementary Figure 1 , see also Segrelles et al., 2002 Segrelles et al., , 2004 . These effects are due to cell autonomous effects, that is, augmented cell proliferation and decreased apoptosis, and to the interaction with the stroma-tumor environment, that is, increased angiogenic response .
The aim of the present study is to investigate potential targets of Akt that may mediate the cell autonomous effects leading to increased tumorigenesis using the PB system. We report that Akt directly controls the expression of specific targets both at the transcriptional and post-transcriptional level. Interestingly, we also found that these alterations were also characteristic of human HNSCC where Akt activity is deregulated.
Results
The specific features of the PB keratinocyte cell line in xenograft experiments (see Introduction) make this system a perfectly suited method to study molecular changes due to Akt-induced transformation. These changes can be further subdivided between those affecting the tumoral injected cells, and those affecting the crosstalk between these cells and the surrounding stroma. In this regard, the increased growth rate in xenografted tumors is associated with increased angiogenesis mediated by post-transcriptional regulation of VEGF . In addition, others and we have previously shown that Akt-mediated inhibition of GSK3b modulates the levels and cellular distribution of cyclin D1 (Diehl et al., 1998; Leis et al., 2002) , which might explain increased proliferation. Here, we explored other mechanisms that might increase the oncogenic potential in a cell-autonomous manner.
Alterations in p21
Cip1/WAF1 , p27 Kip1 , mdm2 and Foxo3a Among the many different Akt targets, the phosphorylation of p21
Cip1/WAF1 and p27
Kip1
, resulting in the altered localization of these proteins, leads to cell cycle progression (Zhou et al., 2001a; Blagosklonny, 2002; Liang et al., 2002; Mayo and Donner, 2002; Shin et al., 2002; Viglietto et al., 2002) . In addition, Akt can also phosphorylate mdm2, favoring mdm2-p53 association and leading to subsequent p53 degradation (Mayo and Donner, 2001; Ogawara et al., 2002; Zhou and Hung, 2002) . Finally, Akt can also phosphorylate several forkhead transcription factors, including Foxo3a, inhibiting the expression of Foxo-regulated genes, which control the cell cycle and cell death (Burgering and Kops, 2002) . Consequently, one might expect that Akt through the direct modulation of the cyclin-dependent kinase inhibitors or indirectly through the downregulation of p53 or Foxo3a activity might increase the cell proliferation in keratinocytes.
We studied the expression and localization of these proteins in tumors obtained with control PB cells or with Akt-transfected cells upon subcutaneous injection. We found that in tumors generated by Akt-transfected keratinocytes, the localization and the expression of p21 Cip1/WAF1 , p27
Kip1 and mdm2 were similar to that found in control tumors (Figure 1a , and data not shown). On the contrary, we also found increased phosphorylation of Foxo3a leading to cytoplasmic localization ( Figure 1a , and data not shown). As expected, we found increased Akt expression ( Figure 1a ) and, concomitantly, increased Akt activity in those tumors generated by Akt-transfected keratinocytes (Figure 1b) . These results indicate that, in this system, the Akt-mediated modulation with p21
Cip1/WAF1 , p27
Kip1 and/or mdm2 observed in other models is not a major responsible factor for the observed increase in tumorigenic behavior.
Increased activation of the Wnt signaling pathway mediated by Akt It has been reported that Akt may interfere with elements of the Wnt pathway leading to increased expression and activity of Wnt effectors (Delcommenne et al., 1998; D'Amico et al., 2000; Desbois-Mouthon et al., 2001; Gotoh et al., 2003) . Moreover, p63 a direct target of PI3K pathway (Barbieri et al., 2003) can also modulate nuclear accumulation of b-catenin (Patturajan et al., 2002; Koga et al., 2003) . To study the possible contribution of this pathway to Akt-induced transformation, we monitored the expression and localization of b-catenin, Lef1 and DNp63a. We found increased expression and increased nuclear accumulation of bcatenin ( Figure 1c 0 and f) and Lef1 ( Figure 1d 0 and f) compared with the correspondent controls ( Figure 1c, d and f). With respect to DNp63a, we found a high number of the tumoral cells expressing this protein in control samples (Figure 1e ). However, this is further increased in Akt-derived samples, which also displayed increased expression ( Figure 1e 0 and f). These data would suggest that Akt may induce the transcriptional activation of b-catenin/Tcf-responsive elements. To monitor this aspect, we performed luciferase reporter assays. We observed that Akt cotransfection induces activity from a reported plasmid containing Wnt-, but not mutant-, responsive elements ( Figure 1g ). These results confirmed that Akt is able to induce the transcriptional activation of the Wnt pathway Akt mediates increased expression and stability of c-myc induced by Akt Among the multiple target genes induced by the bcatenin/Tcf pathway, c-myc and cyclin D1 (Roose and Clevers, 1999; Barker and Clevers, 2000) might be of particular relevance. We monitored c-myc and cyclin D1 gene expression in control and Akt-derived tumors. As expected, Northern blot analysis showed that both genes were expressed to a higher level in those tumors generated by Akt-transfected keratinocytes (Figure 2a) .
At the protein level, others and we have previously shown that Akt mediates an increase in cyclin D1 expression and nuclear localization through the interaction with GSK3b (Diehl et al., 1998; Leis et al., 2002) , concerning c-myc alterations, Western blot analyses and immunostaining ( Figure 2b , c and c 0 ) showed that the level of expression of c-myc is high in those tumors generated by Akt-transfected keratinocytes (Figure 2b , c 0 and d). It is important to remark that c-myc expression is not only regulated by transcriptional mechanisms but also post-transcriptionally. These include increased translation (Prats and Prats, 2002) and stability (Sears et al., 2000) . Augmented translation of cmyc mRNA is mediated by p70S6K and mTOR. As both pathways are activated by Akt in this system , at least part of the increase in cmyc can be due to increased translation. Thus, we monitored the possible increased c-myc stability due to Akt. In this regard, Ser62 phosphorylation of c-myc leads to augmented activity and stabilization, whereas phosphorylation in Thr58, mediated by GSK3b and dependent on the prior Ser62 phosphorylation, leads to c-myc degradation (Sears et al., 2000) . Consequently, we studied the possible alterations in c-myc phosphorylation. Using an antibody reacting with both Ser62/Thr58-phosphorylated c-myc, we found increased c-myc phosphorylation in tumors obtained by subcutaneous injection of Akt-transfected keratinocytes by Western blot ( Figure 2b ) and immunostaining (Figure 2d 0 ). In parallel, we observed increased Ser9 phosphorylation of GSK3b ( Figure 2b ). As this phosphorylation inactivates GSK3b, the results might indicate that Akt mediates this inactivation, thus suggesting that c-myc is stabilized. To confirm this, as it cannot be monitored in tumor samples, we studied possible c-myc stabilization in cultured control and Akt-transfected cells. Increased levels of c-myc and phosphorylated c-myc were observed in pooled clones of Akt-transfected keratinocytes when compared with control cells (Figure 2e ) similar to tumor samples. In addition, the activity of Akt is also increased in cultured cells (Figure 2e 0 ). To investigate the stability of c-myc, protein synthesis was inhibited by treatment with cycloheximide (50 mM) and the levels of c-myc at different times were determined by Western blotting. In parental control cells, the levels of c-myc rapidly decrease being o5% of the initial amounts after Increased activation of the Wnt signaling pathway in mouse skin carcinogenesis The above-commented results provide information on the changes downstream of Akt that occur in tumors induced by transfection of PB keratinocytes with an Akt expression vector. To compare these data with the changes in primary tumors generated in mouse skin by two-stage chemical carcinogenesis, we analysed the expression of the above-commented targets (c-myc CycD and DNp63a) in parallel with Akt and phosphorylated Akt in papillomas and squamous cell carcinomas (SCCs). In addition, we included normal skin and 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-treated skin samples. In agreement with our previous data , we observed ( Figure 3 ) increased activation of Akt, without increased expression, in papillomas and SCC. Similarly, the expression of c-myc, CycD and DNp63a was also increased in tumors (Figure 3) . Furthermore, the expression of GSK3b was increased in papillomas and SCCs, and its activity was downregulated by Ser 9 phosphorylation (Figure 3 ), as we described previously (Leis et al., 2002) . In agreement with such decreased GSK3b activity, we have also found increased b-catenin and Lef1 expression (Figure 3) . Collectively, the results show that the changes observed in the PB keratinocyte system also take place in mouse skin upon two-stage chemical carcinogenesis protocol.
Increased expression and stability of targets is directly induced by Akt
The multiple target proteins induced by increased Akt found in tumors could be directly due to Akt or might be acquired during the extensive in vitro propagation of the cells, leading to increased malignancy. To discriminate between these two possibilities, we carried out the analysis of the above-mentioned elements using parental cells 48 h after the expression of wild-type (wt) Akt. Western blot analyses (Figure 4 ) demonstrate that increased Akt expression leads to increased Akt activity, in parallel with increased cyclin D1, c-myc, b-catenin, Lef1 and DNp63. In addition, increased Akt activity also leads to increased phosphorylation of c-myc and p70S6K. On the contrary, we did not observe altered expression or activity of Ha-ras, ERK1/2 or JNK1/2. In addition, we also monitored the effect of several specific inhibitors: PD98059 (inhibitor of ERK), SB203580 (inhibitor of p38), Wortmanin (inhibitor of PI-3K) and rapamycin (inhibitor of mTOR). This experiment also allowed us to study how other pathways can influence the observed molecular changes. As expected, the levels of cyclin D1 and c-myc decrease in Akt-expressing cells Akt-induced signaling during keratinocyte transformation C Segrelles et al by rapamycin treatment, and in control cells by wortmannin and rapamycin (Figure 3) . In Akt-expressing cells, we also noticed that PD98059 and SB203580 treatment decrease b-catenin levels, whereas PD98059 increases Lef1 expression. This indicates that these other pathways are also involved in the regulation of these molecules through a possible crosstalk with Akt. Finally, DNp63 expression is only moderately affected by rapamycin treatment, indicating that the observed increased levels also were attributable to augmented translation.
The observation that rapamycin treatment decreases the expression of cyclin D1, c-myc and, to a lesser extent, DNp63 and b-catenin prompted us to investigate if rapamycin treatment might affect the tumorigenic behavior of Akt-transfected keratinocytes. To analyse this, we performed subcutaneous injection of Akttransfected keratinocytes in nude mice where a subcutaneous pump that allows a continuous flow of rapamycin for 2 weeks was implanted. We observed that in this period, 6/8 mice in the untreated group Changes in Akt activity and Akt targets in HNSCC Using PB keratinocytes and two-stage carcinogenesis models, we have shown possible Akt targets that can influence the tumorigenic behavior. We next tried to validate these multiple target proteins in human tumors. Human oral dysplasias and HNSCC were selected on the basis of close similarities between them and the tumors derived from mouse skin carcinogenesis protocols (Slaga et al., 1996; Yuspa et al., 1996; Amornphimoltham et al., 2004) . The results of the immunohistochemistry of eight different oral pretumoral dysplasia samples for Akt-P, cytoplasmic and nuclear b-catenin, DNp63, cytoplasmic Foxo3a and c-myc-P and cyclin D1 are summarized in Table 1 (a representative example of immunostaining is shown in Figure 5 ). Given that the maximal Akt activity is provided by serine 473 phosphorylation (Scheid and Woodgett, 2003; Hanada et al., 2004) , we selected specific antibodies against this isoform for immunohistochemistry analysis. All the specimens analysed were found positive for Akt-P, and the staining varies from 25-75% of the cells in the dysplasic area (denoted by 1 or 3 in Table 1 ). The other markers were also quantified similarly by two-blind analysis (0 ¼ negative; 0.5 ¼ 5% or less; 1 ¼ 5-25% cells positive; 2 ¼ 25-75% cells positive; 3 ¼ 75% or more positive cells). Statistical analysis (by t-test) demonstrates a significant linkage between Akt-P and CycD1 (Po0.05), nuclear b-catenin (Po0.01), DNp63 (Po0.05), cytoplasmic Foxo3a (Po0.0001) and, to a lesser extent, c-myc-P (Po0.08).
We next studied 22 HNSCC samples. The results of the immunohistochemistry are summarized in Table 2 . Akt-P and the other markers were also quantified similarly by two-blind analysis. Representative examples of immunostaining of tumors showing Akt-P negative or positive are shown in Figure 6 . For the statistical analysis, tumors were grouped into Akt-P low (showing 0-1 values) and high (showing values X2). Tumors with low Akt-P (10/22; 45.5%) showed a significant reduction of CycD1 (Po0.04), nuclear b-catenin (Po0.0005), DNp63 (Po0.001) and cytoplasmic Foxo3a (Po0.005), but not c-myc-P (Po0.3). On the other hand, tumors showing high Akt-P (12/22; 54.5%) showed a significant increase of CycD1 (Po0.0001), nuclear b-catenin (Po0.00003), c-myc-P (Po0.03) and cytoplasmic Foxo3a (Po0.003), but not DNp63 (Po0.11). It is worth mentioning that in some cases increased Akt-P was found to be in parallel with almost complete absence of Foxo3a staining (Supplementary Figure 2) . Regarding the possible influence of activated Akt on DNp63 expression, it has been recently reported that wt p53, but not certain p53 mutants, associate with DNp63 and targets it into a protein degradation pathway (Ratovitski et al., 2001) . Moreover, the p53-regulated growth arrest and DNA damage-inducible gene product Gadd45a is Foxo3a was considered positive only for cytoplasmic localization. b-catenin was considered positive only for cytoplasmic/nuclear localization. Overall, the results indicate that Akt activation is a frequent event in HNSCC. In addition, we showed that many of the targets downstream of Akt activation observed in the PB and mouse skin tumorigenesis models were also activated early in these tumors, which reinforces that Akt and some of these targets can be considered possible objectives in future preclinical studies.
Discussion
The activation of the PI3K/PTEN/Akt pathway is a common feature in many human cancers, making this an attractive target for molecular therapies. However, a complete characterization to validate these therapeutic targets is a necessary prerequisite. Here, we present evidence for specific mechanisms, due to augmented Akt activity that might mediate increased tumorigenesis in keratinocytes. These mechanisms would be of particular relevance in similar types of tumors in human populations, such as HNSCC. In this regard, previous data have reported activation of Akt in these tumors in humans (Leethanakul et Tables 1 and 2 ).
Our present data support the existence of cell typespecific mechanisms. We failed to detect alterations in p21 Cip1/WAF1 , p27
Kip1 and/or mdm2 (Figure 1 ), proteins that have been described as putative Akt targets in breast cancers (Zhou et al., 2001a, b; Liang et al., 2002; Shin et al., 2002; Viglietto et al., 2002) . However, the majority of HNSCC also display increased p21 Cip1/WAF1 and p27
Kip1 expression, indicating the existence of mechanisms by which some growing tumor cells may tolerate these cell cycle inhibitors (Erber et al., 1997; Warnakulasuriya et al., 1998) . In addition, mdm2 protein is expressed in HNSCC mostly at advanced stages (Ambrosch and Ruschenburg, 2000) . Therefore, it is conceivable that these are not relevant targets in HNSCC.
Wnt pathway is highly relevant in human tumorigenesis (reviewed in Novak and Dedhar, 1999; Roose and Clevers, 1999; Giles et al., 2003) including HNSCC (Leethanakul et al., 2000; Rhee et al., 2002) . Our data also support such involvement downstream of Akt activation in the PB model system (Figure 1 ) and in mouse skin tumorigenesis (Figure 3) . However, the molecular mechanism responsible is not known. One might speculate that the increased DNp63 levels, attributable to increased Akt activity (Barbieri et al., 2003) , may induce inhibition of GSK3b (Patturajan et al., 2002) . This effect, together with the direct ability of Akt to phosphorylate and inhibit GSK3b (Cross et al., 1995; Diehl et al., 1998; Desbois-Mouthon et al., 2002; Leis et al., 2002) can mediate a decrease in phosphorylation levels of b-catenin, which induces Akt-induced signaling during keratinocyte transformation C Segrelles et al nuclear accumulation and activates b-catenin-dependent transcription. In contrast with the present results and our previous data (Leis et al., 2002) , a recent report has shown that inhibition of GSK3b by Ser 9 phosphorylation is not predominant in mouse skin tumors (Bhatia and Spiegelman, 2005) , thus suggesting that Akt activation unlikely plays a major role in the stabilization of b-catenin observed during mouse skin carcinogenesis (Bhatia and Spiegelman, 2005) . This discrepancy, which could be ascribed to different protocols or antibody specificity, would require extensive investigation. Of note, these authors reported increased Tcf-4, but not Lef1 or Tcf-3, expression in parallel with increased Akt activation (Bhatia and Spiegelman, 2005) , whereas it has been shown that Tcf-4 expression is restricted to intestinal and mammary gland epithelium (Barker et al., 1999) . We observed increased expression of Lef1 (Figures 1 and 3) , which could be due to the activation of the autoregulatory loop mediated by the initial increased nuclear accumulation of b-catenin (Filali et al., 2002) . However, other possibilities cannot be discarded at present. In particular, the observed reduc- Note that increased Akt activity (g) is correlated with increased nuclear accumulation of b-catenin (h), increased expression of DNp63 (i), cytoplasmic staining of Foxo3a (j) and nuclear accumulation of CycD1 (k) and c-myc-P (l). Bars ¼ 150 mm.
Akt-induced signaling during keratinocyte transformation C Segrelles et al tion in b-catenin and increased Lef1 as a consequence of PD098059 and SB203580 treatment of Akt-transfected keratinocytes would require further analysis. Importantly, p38 has been recently involved as a negative modulator of DNp63 and, subsequently, b-catenin (Hildesheim et al., 2004) . Among the possible Wnt response genes, cyclin D1 and c-myc are significant in human tumors. Increased cyclin D1 has been associated with mouse skin transformation (Robles and Conti, 1995; Zhang et al., 1997; Rodriguez-Puebla et al., 1998 , whereas cmyc is able to induce skin tumors and also modulates epidermal stem cell homeostasis (Pelengaris et al., 1999; Arnold and Watt, 2001; Waikel et al., 2001) , the primary target in mouse skin cancer (DiGiovanni, 1992; Slaga et al., 1996) . Together with our previous data (Leis et al., 2002) , the results (Figures 2 and 3) indicate that Aktmediated transformation of keratinocytes proceeds through the increased expression of c-myc and CycD1. Interestingly, such increased expression is not only due to transcriptional processes but also post-transcriptional events leading to increased translation and stabilization of c-myc and increased translation and nuclear localization of CycD1 (Leis et al., 2002) . The suggestion that the increased levels of c-myc and CycD1 are also due to increased translation is based on experiments in Aktexpressing keratinocytes. We observed that rapamycin decreases c-myc and CycD1 levels (Figure 4 ), in agreement with previous reports showing that, in both cases, translation is dependent on mTOR/eIF4E pathway (Rosenwald et al., 1995; De Benedetti and Harris, 1999; Bjornsti and Houghton, 2004; Gera et al., 2004) . We also observed that rapamycin treatment leads to a partial decrease in DNp63. As mTOR pathway is also a target of Akt (Nave et al., 1999; Aoki et al., 2001; Gera et al., 2004) , and in this system it can mediate the increased translation of VEGF responsible for the increased angiogenic response , possible drugs affecting this pathway can be considered as attractive targets in cancer therapies. In addition, the reduced tumorigenic potential upon rapamycin treatment highlights the dependence on translational processes in Akt-induced transformation.
HNSCC represent the sixth most common cancer and a major cause of morbidity and mortality due to its relatively poor prognosis. Molecular studies have demonstrated activation of various oncogenes (Ras, Myc, EGFR and cyclin D1) and tumor suppressor gene inactivation (TP53 and p16) in HNSCC. In agreement with previous results (Amornphimoltham et al., 2004; Pedrero et al., 2005) , we provide evidence of the involvement of Akt activation in the development and progression of HNSCC. We also demonstrate that the PB model system recapitulates many of the alterations found in these tumors. In human dysplasias, we observed a predominant activation of Akt, which is correlated with nuclear b-catenin, cytoplasmic Foxo3a, CycD1 and DNp63, whereas minor correlation was found with phosphorylated c-myc. Interestingly, in papillomas produced during two-stage skin carcinogenesis protocols, activation of Akt, increased b-catenin, CycD1 and c-myc is also a common event (Figure 3) . In human HNSCC, we found similar correlation, particularly in those tumors showing Akt activation with a significant increase in nuclear b-catenin, cytoplasmic Foxo3a, CycD1 and phosphorylated c-myc. We also found positive staining for DNp63 in some samples showing reduced Akt activation, whereas low Akt activation is well correlated with low DNp63 levels. These results are in agreement with previous reports showing that DNp63 is overexpressed in the vast majority of HNSCC (Sniezek et al., 2004; Gwosdz et al., 2005; Thurfjell et al., 2005) , and might indicate that, besides Akt, alternative pathways influence such overexpression. Although p53 may be actively involved in this process (Hildesheim et al., 2004) , our data indicated that p53 is not relevant in the modulation of DNP63 expression (Figure 7) . In this regard, amplification of chromosome 3q21-29, where the p63 gene is located, has also been reported in HNSCC (Thurfjell et al., 2005) . In summary, we confirm that Akt activation is a frequent event in HNSCC and, interestingly, in pretumoral dysplasias. Additional studies, including large sample collections and high-throughput techniques, would be required to evaluate whether active Akt represents a marker of diagnostic or prognostic value in HNSCC patients. This would allow one to assess the relevance of possible antitumoral treatments using Akt or its downstream elements as putative targets either at early or late stages of tumor development.
Materials and methods

Tumor induction protocols
To generate tumors in nude mice, upon transfection with control (pcDNA3) or Akt (pcDNA3 Akt) plasmids, PB cells were grown (see below). Upon trypsinization, cells from pooled clones (20-60 different clones) were washed twice and resuspended in PBS (1 Â 10 6 cells/0.1 ml). Afterwards, cell Akt-induced signaling during keratinocyte transformation C Segrelles et al suspensions were subcutaneously injected into nu/nu mice (fiveto six-week-old females; C57Bl/6 strain background) as described . In a set of experiments 2 days after inoculation, a continuous flow pump (Alzet 2002; Alza Corporation, Palo Alto, CA, USA) was surgically implanted on the flank of every mouse near the site of tumor inoculation. The pump was filled with either vehicle or 2 mg of rapamycin (Sigma) in 250 ml PBS supplemented with 5 mg/ml BSA and operated at a flux of 0.5 ml/h for 15 days. Tumors that formed were measured, excised and processed for histopathology analysis, RNA and protein extraction. Similarly sized pieces from different tumors, with similar stromatumor cell content as determined by histopathology, and obtained at the same time points upon subcutaneous injection, were used in biochemical analyses. For two-stage carcinogenesis, dorsal skin of FVB females was shaved in the resting stage of the hair cycle (8-10 weeks of age) and initiated 3 days later with a single dose of 7, 12-dimethyl-benz(a)anthracene (DMBA, Sigma) (100 mg/200 ml in acetone). At 10 days after initiation, mice were subsequently treated twice a week with TPA (Sigma) (5 mg/200 ml in acetone) during 10 weeks. Tumor samples were harvested 30 weeks after initiation and frozen in liquid nitrogen for protein analysis or fixed for histopathological procedures.
Protein extracts and Western blotting
Tumors were ground with a mortar on liquid nitrogen and homogenized in buffer P (Tris, pH 7.5, NaCl 150 mM, EDTA 1 mM, EGTA 1 mM, b-glycerophosphate 40 mM, sodium orthovanadate 1 mM, PMSF 0.1 mM, aprotinin 2 mg/ml, leupeptin 2 mg/ml, NP-40 1%). Cells were pelleted and lysed in the above-mentioned buffer by freeze-thawing cycles. The supernatants after centrifugation at 10 000 r.p.m. for 10 min at 41C were stored at À701C or used directly. Protein concentration in each sample was determined with the Bio-Rad protein assay system (Bio-Rad, Richmond, CA, USA). Cell and tumor proteins were resolved in SDS-PAGE gels and transferred to nitrocellulose (Amersham, IL, USA). Membranes were blocked with 5% nonfat milk in TBS, incubated with appropriate antibodies diluted in TBSTB (0.5% BSA, 0.1% Tween 20 in TBS). Antibodies used were as follows: Akt, mdm2, p21
, p27
Kip1
, cyclin D1, Erk1/2 phospho-Erk 1/2, p38, phospho-p38, DNp63 and c-myc (Santa Cruz Biotechnology, diluted 1/500); b-catenin, JNK, GSK3b-Ser9-P and GSK3b (Transduction Labs, diluted 1/250); c-mycSer58-P-Thr62-P, p70S6K, phospho-JNK, p70S6K-P and phospho Foxo3a (Cell Signaling Technology, diluted 1/500); and Lef1 and Foxo3a (Upstate, diluted 1/300). Actin or tubulin (Santa Cruz Biotechnology, diluted 1/1000) was used throughout the experiments to confirm equal loading. Secondary antibodies anti-rabbit, anti-mouse or anti-goat IgG were purchased from Jackson Immunoresearch and used 1/2000 in TBSTB. WestPicoSignal (Pierce, Rockford, IL, USA) was used to detect the bands according to the manufacturer's recommendations.
Northern blotting
Total RNA from frozen tumors was isolated by Trizol extraction. Northern blots containing total RNA (20 mg/lane) were probed for the expression of CycD1 and c-myc. DNA probes were prepared by random primed reactions using the complete sequences as described previously (Paramio et al., 1999) . The membranes were also hybridized with a 7S RNA probe to verify that equal amounts of mRNA were loaded and transferred.
Akt kinase assay Akt activity in tumors extracts was determined after immunoprecipitation with anti-Akt (Santa Cruz, C-20 antibody 1 ml/ 25 mg protein) essentially as described (Paramio et al., 2001; Santos et al., 2002; Segrelles et al., 2002) using histone 2B (Roche Molecular Biochemicals) as substrate. Autoradiograms were subsequently quantified using a Phosphorimager (Bio-Rad).
Cell culture and transfection Pooled clones (>40) of PB keratinocytes transfected with plasmid coding for wt Akt (pcDNA3Akt) or control (pcDNA3) , selected by growing in the presence of G418 (0.5 mg/ml) for 3-4 weeks, were cultured in Dulbecco's modified Eagle's medium (DMEM) (Life technologies) supplemented with 10% of fetal calf serum (BioWhitakker, Walkersville, MD, USA). Cycloheximide was purchased from Sigma and used at 50 mM (final concentration).
Luciferase assays were performed upon transfection essentially as described . Briefly, cells were cultured in DMEM (GibcoBRL) supplemented with 10% fetal bovine serum and antibiotics. Transient transfections were performed with the Lipofectamine reagent (GibcoBRL) according to the manufacturers' protocol. At 36 h after transfection, cells were harvested for luciferase assays (Promega Dual-Luciferase Kit). Firefly luciferase values were standardized to Renilla luciferase values (pRL-SV40; Promega) to account for differences in transfection efficiency between samples. As a control, the aˆ-catenin/Lef1 reporter (TOPflash) was replaced by a mutant (FOPflash) reporter to ensure that values were dependent on the Lef1/Tcf-binding sites in the promoter. Plasmids coding for wt Akt, TOPflash and FOPflash were provided by Dr JS Gutkind (NIDCR/NIH).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue specimens from head and neck cancer patients were retrieved from the archives of Department of Pathology, '12 de Octubre' University Hospital. Formalin-or ethanol-(70%) fixed, paraffin-embedded tumor samples upon subcutaneous injection, or formalin-fixed human HNSCC samples were sectioned (6 mm thick). All tissues were stained H&E for pathological diagnosis. Sections were dewaxed and treated by microwave boiling in citrate buffer, blocked by incubation in 10% nonimmune horse serum and incubated with the primary antibodies overnight at 41C (see Western blotting section). After exhaustive washing in PBST, sections were incubated with appropriate biotin-coupled secondary antibodies (all 1/1000 in PBST) followed by avidin-peroxidase (ABC elite kit Vector, Burlingame, CA, USA). Positive staining was determined using diaminobenzidine as a substrate (DAB kit Vector, Burlingame, CA, USA) following the manufacturer's recommendations. Sections were then counterstained with hematoxylin and mounted. At least 10 different tumors for xenograft experiments of each type were analysed. Controls omitting primary antibodies or after the preincubation of the antibodies with the immunizing peptide were routinely performed (not shown). Statistical analyses were performed using SPSS software.
Abbreviations SCC, squamous cell carcinoma; TPA, 12-O-tetradecanoylphorbol-13-acetate; DMBA, 7, 12-dimethyl-benz(a)anthracene.
